There are 2789 resources available
476P - Open-label phase I/II study evaluating the tolerability and antitumor activity of selinexor (SEL) and pembrolizumab (pembro) in colorectal cancer (CRC)
Presenter: Talia Shentzer Kutiel
Session: ePoster Display
477P - Utilisation and predictors of genomic testing prior to first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC)
Presenter: Heinz Josef Lenz
Session: ePoster Display
478P - TA-ness classification discriminates RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) who may benefit from antiEGFR treatment
Presenter: Cristina Santos
Session: ePoster Display
479P - Difference gene mutations among CRC patients with MSS and MSI-H types in China
Presenter: Jianjun Yang
Session: ePoster Display
480P - Gene expression of NANOG and NANOGP8 in colorectal cancer
Presenter: Hiroyuki Arai
Session: ePoster Display
462P - Heterogeneity of mismatch repair status between primary tumors and matched metastases in metastatic colorectal cancer
Presenter: David Tougeron
Session: ePoster Display
483P - The correlation analysis between MUC16 mutation and immunotherapy predictive biomarkers in colon adenocarcinoma
Presenter: Gong Chen
Session: ePoster Display
484P - CD300c blockade promotes anti-cancer immunity and synergizes with immune checkpoint inhibitor in colon cancer
Presenter: HyeRim Shin
Session: ePoster Display
464P - Exome sequencing of ctDNA portrays the mutational landscape of patients with relapsing colon cancer and indicates new actionable targets
Presenter: Noelia Tarazona
Session: ePoster Display